Regeneron Announces Closing of Underwritten Offering of Common Stock; Raises $175.1M

Regeneron Pharmaceuticals, Inc.

announced today the completion of its previously announced underwritten public offering of 5,500,000 shares of Common Stock, as well as 825,000 additional shares of its Common Stock pursuant to the full exercise of the over-allotment option granted to the underwriter. The total proceeds of the offering (before estimated offering expenses) were approximately $175.1 million. Citi acted as the sole book-running manager for the offering. The shares were offered by Regeneron under the Company's shelf registration statement.